Article info
PDFBasic research
Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure
- Correspondence to:
Professor Hugh Watkins
Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK; hugh.watkins{at}cardiov.ox.ac.uk
Citation
Heterozygous disruption of SERCA2a is not associated with impairment of cardiac performance in humans: implications for SERCA2a as a therapeutic target in heart failure
Publication history
- Accepted March 30, 2005
- First published April 21, 2005.
Online issue publication
March 15, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Heart